LEVEL OF ERRORS, CHANGE IN DIAGNOSIS AND THEIR IMPACT ON MANAGEMENT IN CASES REFERRED FOR SECOND OPINION
Madeeha Anwar, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim, Shahid Jamal*, Hamza Mansur
Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *Watim Medical College Rawalpindi Pakistan

ABSTRACT
Objective: To determine the frequency of change in diagnosis and level of errors in cases referred to Armed Forces Institute of Pathology for second opinion and their impact on modifications of treatment and prognosis.
Study Design: Cross sectional study.
Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, form Mar to Oct 2017.
Methodology: All the cases referred for review diagnosis were tested by applying panel of immunohistochemical markers and special stains on formalin fixed paraffin embedded tissue sections as decided on morphology. Level of errors were defined as level I error: minor discrepancy with no impact on management, level II: minor discrepancy with impact on management, level III: main category remains same but there was change/confirmation of specific diagnostic entity with an impact on management and level IV: gross changes in diagnosis with significant impact on management. Level IV was further subdivided into IV a: benign misdiagnosed as malignant, IV b: malignant misdiagnosed as benign and IV c: changes in tumor subtype.
Results: A total of 100 cases, where review diagnosis was changed were included. Minor discrepancies (level I and level II) were observed in only 7% cases with little or no impact on the management. Most frequent discrepancy observed as level III in 75% cases. Major discrepancy (level IV errors) was noted in 18% cases.
Conclusion: There were high discrepancy rates between previous diagnosis and review diagnosis. The higher use of extended panels of immunohistochemistry markers were the most likely explanations.
Keywords: Discrepancy in diagnosis, Immunohistochemistry, Review diagnosis, Second opinion.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION
Several studies reported the advantages of obtaining second opinion for more accurate diagnosis1,2. Second opinion after initial histopathological diagnosis is required in different situations3-6. The criteria when to get the second opinion vary considerably3. It may be needed for the patient/relatives satisfaction and if clinical impression of treating clinician does not tally with histological diagnosis. Sometimes second opinion is required when the patient is not responding to the treatment being given after initial diagnosis4. Such second opinions help to expose diagnostic errors and helps in proper management of patient5. Hamdani et al, reported 72% discrepancy between initial and review diagnosis6. In the same study, different categories of discrepancies have also been discussed. In Pakistan, surgical pathology is still evolving as a science and clinicians are becoming increasingly aware of the importance of an accurate surgical pathology diagnosis for the treatment of their patients. While the basic aim of the practice of surgical pathology is to provide accurate diagnosis, it is equally essential to prevent an erroneous diagnosis, which can result in serious errors in the treatment and prognosis of the patient. In a developing country like Pakistan most of the centers lack the facility of immunohistochemistry and special stains, which is thought to be essential for the diagnosis in many cases, and this further necessitates the importance of second opinion from more specialized referral centers. The section of Histopathology at Armed Forces Institute of Pathology (AFIP) Rawalpindi is serving as the major referral center for diagnostic surgical pathology. With the aid of extended immunohistochemical panel and special stains, accurate diagnosis has been made possible and subsequent change in the diagnosis of referred cases for review has a huge impact on the modification of management of patients.

The purpose of this study was to review the cases sent to AFIP for second opinion and to determine the changes in the diagnosis and to ascertain level of errors in the diagnosis. The results would help to establish the significance of acquiring second opinion and use of extended panel of immunohistochemistry for accurate diagnosis and subsequent benefit for the patient and also to ascertain various level of errors in the diagnosis of histopathological cases.

Correspondence: Dr Madeeha Anwar, Department of Histopathology, Armed Forces institute of Pathology, Rawalpindi Pakistan
Received: 15 Jan 2019; revised received: 26 Sep 2019; accepted: 31 Oct 2019
METHODOLOGY
This descriptive cross-sectional study was carried out at the AFIP, Rawalpindi, after taking approval from Institutional Review Board (certificate reference no: FC-HSP16-17/READ-IRB/17/416). A total of 100 cases, referred for second opinion to the department of Histopathology, from March to October 2017 were enrolled for the study. Cases for second opinion were received as paraffin blocks or slides and assigned new departmental number. Tissue was cut into sections by tissue microtome so that each section is not >5 microns thick. Slides were stained with Haematoxylin & Eosin (H&E) staining. The Immunohistochemical markers and special stains were applied as per differential diagnosis made on H&E slide and according to the manufacturer's guidelines. Immunohistochemistry results were interpreted on high power field objective. With the baseline guidance from categories of diagnostic errors, mentioned in the study by Hamdani et al., various level of errors have been defined as level I error: minor discrepancy with no impact on management, level II error: minor discrepancy with impact on management, level III error: main category remains same but there is change/confirmation of specific diagnostic entity with an impact on management and level IV error: gross changes in diagnosis with significant impact on management. Level IV was further subdivided into IV a: benign misdiagnosed as malignant, IV b: malignant misdiagnosed as benign and IVc: changes in tumor subtype. Statistical software SPSS 21 was used for description and analysis of result.

RESULTS
A total of one hundred (n=100) review cases with subsequent change in the diagnosis were analyzed for various diagnostic errors. Minor discrepancies (level I and level II) and major discrepancy (Level IV errors with significant impact on management) were observed less frequently. Whereas, bulk of the cases were found to be falling in the category of Level III errors. The detailed distribution of these errors is shown in figure. Level III and Level IV errors are further elaborated in table-I & II respectively.

DISCUSSION
Our study result showed that most frequent discrepancy observed as Level III (main category remains same but there was change/confirmation of specific diagnostic entity with an impact on management) in
75% cases. Major discrepancy (level IV errors) was noted in 18% cases. In study previously conducted at the same department in 2006-7, reported concurrence rate between initial and review diagnosis was 53%. There were 23.5% of cases where major discrepancy was found resulting in the change in management. They applied immunohistochemistry markers in 64% of cases while we applied in all cases. In another similar study at our department conducted in 2012, diagnostic agreement was reported as 49.3%, where there was no change in the review diagnosis and in 50.7% of cases discrepancies were found and the review diagnosis was changed. In the present study diagnostic agreement was observed in only 7% cases where only minor discrepancies were observed with no/negligible impact on the management. During this time we have made extended panel of immunohistochemistry markers available at AFIP, which were helpful in making exact diagnosis and subtyping of tumor. Moreover, in the previous study immunohistochemistry markers were applied in 74% of cases while we applied those markers in all (100%) cases. These could be the possible explanations of higher discrepancy rates in the present study. In a similar study, Somcutian et al, evaluated the degree of concordance among histological diagnosis of sarcomas between non-specialized pathology center and highly specialized pathology center in Europe. They reported that complete diagnostic agreement was achieved in 62.5% of cases. Partial disagreement was achieved in 26.1% and major disagreement was observed in 11.4% of cases. They concluded that immunohistochemistry was the major responsible factor followed by difficulties in the interpretation of the morphology. Diagnostic agreement rate was much lower in our study, likely due to difference in defining the discrepancy, however, major discrepancy rate (18%) in our study are comparable with their study. Al-Ibraheemi et al, reported 71% diagnostic agreement with a major discrepancy rate of 8%. Thway et al, in their study found diagnostic agreement in 250 cases (71.8%), with 57 (16.4%) major discrepancies. In a multicentral study from Europe, referral for second opinion showed a complete diagnostic agreement in 56%, partial agreement in 35% and complete disagreement in 8% of cases. The high variation in diagnostic agreements and discrepancy rates across the studies might be in part due to different definitions used for labeling discrepancy levels, variation in the panel of immunohistochemistry markers used in these studies and the impact of using molecular diagnostics and other ancillary tests in aid to the final diagnosis. All these factors can contribute to the variation in discrepancy rates observed across various studies. In our setup we do not use molecular diagnostic techniques.

Although, in routine clinical practice, the idea of getting second opinion in every case seems quite daunting, yet the higher rates of disagreements reported in several studies is of grave concern. This variability in pathological diagnosis eventually results in high financial burden and also includes consequences of incorrect treatment in the form of higher morbidity and mortality rates. It has also been hypothesized that poor inter-professional collaborations and coordination may have an adverse impact on delivery of services and care of patients. Case reviews and discussions at multidisciplinary team meetings have been evolved into standard practice with an aim to provide evidence-based management recommendations. The major advantages observed from such multidisciplinary meetings were competence development and patient support. In a recent study, main barriers to a joint treatment recommendation were reported to be need for supplementary investigations and insufficient pathology reports. Pillay et al, conducted a systematic review to evaluate the empirical benefits of such multidisciplinary team meetings and reported that between 4% and 45% of patients discussed at such meetings experienced changes in diagnostic reports after the meeting, which were likely more accurate. However, there was little evidence about improvement in clinical outcomes. Several strategies have been assessed for improving delivery of healthcare services in low income countries. It has been reported that lack of coordination of care and lack of research addressing coordination of care are the main areas need to be focused in these countries. We suggest future research at our settings aiming towards number of interventions that can improve inter-professional collaborations.

We suggest establishing regular multidisciplinary meetings with other surgical pathology departments referring their cases for second opinion. We argue that the quality of decision making process in multidisciplinary meetings largely depend upon the quality of information being presented. Hahlweg et al, in their recent study demonstrated that there were great differences in quality of different aspects of information presented at these meetings. Final recommendations varied significantly and time constraints were found to play a major role. Furthermore, healthcare professionals encounter various problems when collaborating in
clinical practice and conducting regular multidisciplinary team meetings needs considerable investment of time and finances. In recent times, health informatics have been developed as an integrating factor for academic professionals to work as inter-professional healthcare teams for better practices and overall management of patients. We also suggest implying modern health informatics system at our settings to tackle these problems. Modern day telemedicine techniques could be used to achieve these outcomes. This will help in presenting the quality information to the panel of experts sitting at a distance and also will reduce investment of time and finances. More accurate diagnosis concluded from these telemedicine sessions would also help to reduce the financial burden incurred to the patients and could also reduce the consequences of incorrect treatment based in inaccurate diagnosis. We also encourage seeking benefit from ancillary molecular diagnostic tools for achieving diagnostic accuracy.

ACKNOWLEDGMENT

We would like to acknowledge all the studied patients for their cooperation. We wish to pay special gratitude to our families and friends for their continuous support and motivation.

CONCLUSION

Our study result showed high discrepancy rates for level-III and level-IV errors. The use of extended panels of immunohistochemistry markers were the most likely explanations. Based on our study results we encourage getting second opinion for difficult cases, whether this opinion is in the form of intradepartmental meeting or getting review from another advanced lab. We suggest implying modern day telemedicine techniques to reduce the burden on our healthcare system due to referral for second opinion in substantial number of cases. This will help in presenting the quality information to the panel of experts sitting at a distance and also will reduce investment of time and finances.

CONFLICT OF INTEREST

This study has no conflict of interest to be declared by any author.

REFERENCE

1. Elmore JG, Longton GM, Carney PA. Diagnostic concordance among pathologists interpreting breast biopsy specimens. J Am Med Assoc 2015; 313(11): 1122-32.
2. Davidson NE, Rimm DL. Expertise vs evidence in assessment of breast biopsies: an atypical science. J Am Med Assoc 2015; 313(11): 1109-14.
3. Geller BM, Nelson HD, Carney PA. Second opinion in breast pathology: policy, practice and perception. J Clin Pathol 2014; 67(11): 955-60.
4. Manion E, Cohen M, Weydert J. Mandatory second opinion in surgical pathology referral material: Clinical consequences of major disagreements. Am J Surg Pathol 2008; 32(5): 732-37.
5. Elmore JG, Tosteson NA, Pepe MS. Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. Br Med J 2016; 353(1): i306974-78.
6. Hamdani SNR, Mustaq S, Mamoon N, Khadir MT, Muhammad AS. Second Opinion in Pathology of Lymphoid Lesions–An Audit. Pak J Med Sci 2008; 24(66): 798-802.
7. Ahmed Z, Azad NS, Bhurgari Y, Ahmed R, Kayani N, Pervez S, et al. Significance of immunohistochemistry in accurate characterization of malignant tumors. J Ayub Med Coll Abbottabad 2006; 8(2): 38-43.
8. Sharif MA, Hamdani SN. Second opinion and discrepancy in the diagnosis of soft tissue lesions at surgical pathology. Ind J Pathol Microbiol 2010; 53(3): 460-64.
9. Somcutian O, Buiga R, Galatir M, Tudor Eniu D, Racieriuc B, Coza D, et al. Histopathological diagnostic concordance in bone and soft tissue sarcomas between two comprehensive cancer centers from eastern and western Europe: a collaborative experience. Ann Pathol 2015; 35(1): 32-40.
10. Al-Ibraheemi A, Folpe AL. Voluntary second opinions in pediatric bone and soft tissue pathology: a retrospective review of 1601 cases from a single mesenchymal tumor consultation service. Int J Surg Pathol 2016; 24(8): 685-91.
11. Tway K, Wang J, Mobako T, Fisher C. Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre. reassessment in the era of ancillary molecular diagnosis. Sarcoma 2014; 2014; 686902.
12. Ray-coquard I, Montesco MC, Coindre JM. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Annals Oncol 2012; 23(9): 2442-47.
13. Neuville A, Ranchère-Vince D, Dei Tos AP. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. Am J Surg Pathol 2013; 37(8): 1259-68.
14. Middleton LP, Feeley TW, Albright HW, Walters R, Hamilton SH. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste. J Oncol Pract 2014; 10(4): 275-80.
15. Reeves S1, Pelone F, Harrison R, Goldman J, Zwarenstein M. Interprofessional collaboration to improve professional practice and healthcare outcomes. Cochrane Database Syst Rev 2017; 6(6): CD000072-75.
16. Rosell L, Alexandersson N, Hagberg O, Nilbert M. Benefits, barriers and opinions on multidisciplinary team meetings: a survey in Swedish cancer care. BMC Health Serv Res 2018; 18(1): 249-52.
17. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev 2016; 42(1): 56-72.
18. Ciapponi A, Lewin S, Herrera CA, Opiyo N, Pantoja T, Paulsen E, et al. Delivery arrangements for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev 2017; 9(9): CD011083-86.
19. Hahlweg P, Didi S, Kriston L, Härter M, Nestoriuc Y, Scholl I. Process quality of decision-making in multidisciplinary cancer team meetings: a structured observational study. BMC Cancer 2017; 17(1): 772-76.
20. Holden RJ, Binkheder S, Patel J, Viernes SHP. Best Practices for Health Informatician Involvement in Interprofessional Health Care Teams. Appl Clin Inform 2018; 9(1): 141-48.